Description: Cengild Medical Berhad, an investment holding company, operates a medical center in Malaysia. The company offers various care and treatment consultant services for gastrointestinal and liver diseases, morbid obesity, and oncology and urological conditions; general cardiology and gynecology assessment; gastroenterology and hepatology; anesthesiology, endocrinology, general surgery, internal medicine, orthopedic, plastic and reconstructive surgery, radiology, rheumatology, and thoracic surgery; ear, nose and throat; gastrointestinal surgeries, including upper gastrointestinal, hepatobiliary, pancreatic, colorectal surgery, and bariatric surgery; and chemotherapy. It also provides medical management services; nursing services and clinical support services; clinical laboratory and pharmacy; radiology and imaging services; dietetics and nutrition, physiotherapy, and medical record services; accident and emergency care, and health screenings; and consultant services. Cengild Medical Berhad was founded in 2017 and is based in Kuala Lumpur, Malaysia.
Home Page: cengild.com
Nexus @ Bangsar South
Kuala Lumpur,
59200
Malaysia
Phone:
60 3 2242 7000
Officers
| Name | Title |
|---|---|
| Dr. Huck Joo Tan | Executive Chairman & Medical Director |
| Dr. Mohamed Akhtar Bin Mohamed Ditali Qureshi | Head of Medical Adv. Board and Operating Theatre & Central Sterile Supply Dept. and Exec. Director |
| Ms. Wai Fern Lee | Group Chief Executive Officer |
| Mr. Yoon Ahn Lian | Financial Controller |
| Dr. Siew Kuen Ong | Head of Department, Medicine & Endoscopy |
| Dr. Ramesh K. Gurunathan | Head of Inpatient Department |
| Dr. Mustafa Mohammed Taher | Head of Outpatient Department |
| Mr. Thiam Chai Tee | Company Secretary |
| Ms. Siew Yeen Wong MAISCA | Company Secretary |
Exchange: KLSE
Country: MY : Malaysia
Currency: Malaysian Ringgit (RM)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 28.5 |
| Price-to-Book MRQ: | 2.1145 |
| Price-to-Sales TTM: | 3.5508 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 159 |